COMPARISON OF CLASS-SPARING TO 3-DRUG REGIMENS FOR INITIAL HIV THERAPY

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这是一项III期、随机、三组、开放标签的研究，比较了以下三种方案对HIV感染初始治疗的有效性：以非核苷类逆转录酶抑制剂（NNRTI）为基础的方案(依非韦伦（EFV) +司他夫定缓释（d4T XR）[或齐多夫定（ZDV）或替诺福韦（TDF）] + epivir (3TC)），以（利托那韦）RTV增强蛋白酶抑制剂（PI）为基础的方案（洛匹那韦LPV/RTV + d4T XR[或ZDV或TDF] + 3TC），以及核苷类逆转录酶抑制剂（NRTI）保留方案（EFV + LPV/RTV）。本研究将招募660名hiv -1感染、未接受抗逆转录病毒治疗（ARV）的男女受试者，年龄在18岁至18岁之间。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase III, randomized, 3-arm, open-label study comparing the effectiveness of the following three regimens for the initial treatment of HIV infection: a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen (efavirenz (EFV) + stavudine-extended release (d4T XR) [or zidovuidine (ZDV) or tenofovir (TDF)] + epivir (3TC), a (ritonavir) RTV-enhanced protease inhibitor (PI)-based regimen (lopinavir LPV/RTV + d4T XR [or ZDV or TDF] + 3TC), and, a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen (EFV + LPV/RTV). This study will enroll 660 HIV-1-infected, ARV (antiretroviral)-naive male and female subjects >18 years of age.